JAMA Psychiatry
March 1, 2017
Gerard Sanacora, Mark A. Frye, William M. Mcdonald et al.
577 citations
Ketamine can produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. However, existing studies have relatively small sample sizes, lack longer-term data on efficacy, and provide limited data on safety. Despite these limitations, ketamine is increasingly used off-label for mood and other psychiatric disorders. This review and consensus statement provides an overview of the data, highlights limitations, and offers suggestions to facilitate evidence-based clinical decision-making and patient safety.
The Journal of Clinical Psychiatry
August 25, 2024
Mark A. Frye, Balwinder Singh, Scott Breitinger et al.
2 citations
A man with alcohol use disorder (AUD) maintained sobriety while taking an SSRI and naltrexone, but stopped the SSRI to take part in a psilocybin ceremony, after which he relapsed to alcohol use. The case examines factors that likely contributed to the relapse, including the discontinuation of the SSRI, the context of the psilocybin experience, and the absence of structured follow-up care.
The Journal of Clinical Psychiatry
September 17, 2025
Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
1 citation
Ketamine and esketamine reduced long-term emergency department visits for suicidality among individuals with treatment-resistant depression. Further research with longer follow-up is needed to determine whether these benefits depend on mood state or reflect an independent mechanism.